SciVision Biotech Inc (1786) — Cash Flow Quality Index
SciVision Biotech Inc (1786) has a Cash Flow Quality Index of 2.21x as of March 2026. Operating cash flow of NT$48.51 Million exceeds net income of NT$21.96 Million, indicating high earnings quality where cash backs reported profits. Explore how well can SciVision Biotech Inc service its debt to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
SciVision Biotech Inc Cash Flow Quality Index (2011–2025)
Historical Cash Flow Quality Index for SciVision Biotech Inc across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see 1786 operating cash flow.
Annual Cash Flow Quality Index for SciVision Biotech Inc (2011–2025)
Year-by-year earnings quality comparison for SciVision Biotech Inc.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.76x | NT$123.99 Million | NT$162.34 Million | ▼ -31.4% |
| 2024 | 1.11x | NT$269.87 Million | NT$242.25 Million | ▼ -27.1% |
| 2023 | 1.53x | NT$272.01 Million | NT$177.90 Million | ▲ +48.9% |
| 2022 | 1.03x | NT$178.21 Million | NT$173.55 Million | ▲ +21.0% |
| 2021 | 0.85x | NT$98.51 Million | NT$116.06 Million | ▲ +2.3% |
| 2020 | 0.83x | NT$126.47 Million | NT$152.49 Million | ▼ -45.5% |
| 2019 | 1.52x | NT$204.40 Million | NT$134.28 Million | ▲ +26.9% |
| 2018 | 1.20x | NT$111.70 Million | NT$93.10 Million | ▲ +70.2% |
| 2017 | 0.70x | NT$15.98 Million | NT$22.67 Million | ▼ -33.8% |
| 2015 | 1.06x | NT$49.81 Million | NT$46.77 Million | ▼ -10.4% |
| 2013 | 1.19x | NT$37.27 Million | NT$31.36 Million | ▲ +44.0% |
| 2012 | 0.83x | NT$51.52 Million | NT$62.43 Million | ▲ +13.7% |
| 2011 | 0.73x | NT$37.13 Million | NT$51.16 Million | — |